As a known negative modulator of antioxidant protein thioredoxin, TXNIP has emerged as a promising target in a number of diseases like gouty arthritis [22], cervical inflammation [23], and central nervous system-related injuries or diseases [24, 25]. The gene discussed is TXN; the disease is gout.